CASE REPORT
Diagnostic difficulties in a patient with precocious puberty and short stature observed for Kabuki syndrome
 
More details
Hide details
1
Students’ Scientific Society, Department of Pediatrics and Pediatric Endocrinology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Katowice, Poland
 
2
Department of Pediatrics and Pediatric Endocrinology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Katowice, Poland
 
 
Submission date: 2025-03-21
 
 
Final revision date: 2025-07-06
 
 
Acceptance date: 2025-07-09
 
 
Publication date: 2025-10-15
 
 
Corresponding author
Ewa Błaszczyk
Ewa Błaszczyk, Department of Paediatrics and Paediatric Endocrinology, School of Medicine in Katowice, Medical University of Silesia, 16 Medyków St., 40-752 Katowice, Poland
 
 
Pediatr Pol 2025;61(4):381-386
 
KEYWORDS
TOPICS
ABSTRACT
Kabuki syndrome (KS) is a rare dysmorphic syndrome characterized by multiple congenital anomalies and developmental disorders. The presented patient, who was born with weight and length too small for gestational age, was found to have multiple co-occurring disorders, including endocrinopathy – low growth and true (central, gonadotropin-releasing hormone-dependent) precocious puberty. In order to inhibit premature puberty and improve the prognosis of final height, treatment with triptorelin was initiated at the age of eight years and continued for a further 5 years. Next-generation sequencing was performed, which revealed a variant of uncertain clinical significance, which made it impossible to unequivocally diagnose KS. In this article, we describe the long process of seeking a diagnosis for rare genetic diseases.
REFERENCES (23)
1.
Boniel S, Szymańska K, Śmigiel R, Szczałuba K. Kabuki syndrome – clinical review with molecular aspects. Genes (Basel) 2021; 12: 468. DOI: 10.3390/genes12040468.
 
2.
Schott DA, Blok MJ, Gerver WJM, et al. Growth pattern in Kabuki syndrome with a KMT2D mutation. Am J Med Genet A 2016; 170: 3172-3179.
 
3.
Adam MP, Hudgins L, Hannibal M. Kabuki syndrome. 2011 Sep 1 [Updated 2022 Sep 15]. In: Adam MP, Feldman J, Mirzaa GM, et al. (eds.). GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2024. Available from: https://www.ncbi.nlm.nih.gov/b....
 
4.
Di Candia F, Fontana P, Paglia P, et al. Clinical heterogeneity of Kabuki syndrome in a cohort of Italian patients and review of the lite­rature. Eur J Pediatr 2022; 181: 171-187.
 
5.
Chang YM, Pan YW, Chou YY, et al. A boy with a progressive neurologic decline harboring two coexisting mutations in KMT2D and VPS13D. Brain Dev 2023; 45: 603-607.
 
6.
Aristizábal E, Diaz-Ordóñez L, Candelo E, Pachajoa H. A novel intronic KMT2D variant as a cause of Kabuki syndrome: a case report. Appl Clin Genet 2021; 14: 409-416.
 
7.
Li Z, Ning Z. Neonatal Kabuki syndrome caused by KMT2D mutation: a case report. Medicine (Baltimore) 2023; 102: e36681. DOI: 10.1097/MD.0000000000036681.
 
8.
Niklasson A, Albertsson-Wikland K. Continuous growth reference from 24th week of gestation to 24 months by gender. BMC Pediatr 2008; 8: 8. DOI: 10.1186/1471-2431-8-8.
 
9.
 
10.
Bögershausen N, Wollnik B. Unmasking Kabuki syndrome. Clin Genet 2013; 83: 201-211.
 
11.
Thomas IT, Gaitantzis YA, Frias JL. Palpebral fissure length from 29 weeks gestation to 14 years. J Pediatr 1987; 111: 267-268.
 
12.
Cheon CK, Ko JM. Kabuki syndrome: clinical and molecular charac­teristics. Korean J Pediatr 2015; 58: 317-324.
 
13.
Barry KK, Tsaparlis M, Hoffman D, et al. From genotype to phenotype – a review of Kabuki syndrome. Genes (Basel) 2022; 13: 1761. DOI: 10.3390/genes13101761.
 
14.
Schott DA, Gerver WJM, Stumpel CTRM. Growth hormone the­rapy in children with Kabuki syndrome: 1-year treatment results. Horm Res Paediatr 2017; 88: 258-264.
 
15.
Latronico AC, Brito VN, Carel JC. Causes, diagnosis, and treatment of central precocious puberty. Lancet Diabetes Endocrinol 2016; 4: 265-274.
 
16.
Eugster EA. Treatment of central precocious puberty. J Endocr Soc 2019; 3: 965-972.
 
17.
https://www.gov.pl/web/zdrowie...- z-dnia-18-grudnia-2024-r-w-sprawie-wykazu-refundowanych- lekow-srodkow-spozywczych-specjalnego-przeznaczenia-zywieniowego-oraz-wyrobow-medycznych-na-1-stycznia-2025-r (Accessed: 17.05.2025).
 
18.
Moon JE, Lee SJ, Ko CW. A de novo KMT2D mutation in a girl with Kabuki syndrome associated with endocrine symptoms: a case report. BMC Med Genet 2018; 19: 102. DOI: 10.1186/s12881-018-0606-9.
 
19.
Vargas-Uricoechea H, Nogueira JP, Pinzón-Fernández MV, Schwarzstein D. The usefulness of thyroid antibodies in the diagnostic approach to autoimmune thyroid disease. Antibodies (Basel) 2023; 12: 48. DOI: 10.3390/antib12030048.
 
20.
Ming JE, Russell KL, McDonald-McGinn DM, Zackai EH. Autoimmune disorders in Kabuki syndrome. Am J Med Genet A 2005; 132A: 260-262.
 
21.
So PL, Luk HM, Yu KPT, et al. Clinical and molecular characterization study of Chinese Kabuki syndrome in Hong Kong. Am J Med Genet A 2021; 185: 675-686.
 
22.
Zenker M, Mohnike K, Palm K. Syndromic forms of congenital hyperinsulinism. Front Endocrinol (Lausanne) 2023; 14: 1013874. DOI: 10.3389/fendo.2023.1013874.
 
23.
Rapp T, Kalinousky AJ, Johnson J, et al. Sleep disturbance is a common feature of Kabuki syndrome. Am J Med Genet A 2022; 188: 3041-3048.
 
Journals System - logo
Scroll to top